Kelly Pelton, MD
Internal Medicine · Kerrville, TXNPI 1356347868
Payments from drug & device makers
Across 143 payments — averaging $24.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$847
- AbbVie$603
- Astellas Pharma US Inc$335
- Lilly USA, LLC$176
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$171
- GSK$168
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,24294%
- Education$1996%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 31 | $847 |
| AbbVie(2 entities) | 29 | $603 |
| Astellas Pharma US Inc | 11 | $335 |
| Lilly USA, LLC | 4 | $176 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $171 |
| GSK | 4 | $168 |
| Urovant Sciences Inc | 3 | $162 |
| Mayne Pharma Commercial LLC | 6 | $133 |
| Currax Pharmaceuticals LLC | 6 | $102 |
| Exact Sciences | 5 | $97 |
| Therapeuticsmd, Inc. | 5 | $77 |
| Abbott | 1 | $60 |
| Novo Nordisk | 3 | $53 |
| Sumitomo Pharma America, Inc. | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Revance Therapeutics, Inc. | 1 | $29 |
| Bausch Health US, LLC | 1 | $26 |
| Exeltis, USA Inc. | 1 | $23 |
| Pfizer | 1 | $22 |
| Novartis | 1 | $22 |
| Organon | 1 | $21 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Boston Scientific | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Alkermes, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Avion Pharmaceuticals | 1 | $14 |
| Acessa Health Inc. | 1 | $14 |
| Lupin Inc. | 1 | $13 |
| Aspira Women's Health Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,441 in reported general payments places this provider in the 80th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 47 | $43,347 |
| OzempicSemaglutide | 39 | $41,235 |
| EliquisApixaban | 32 | $38,336 |
| TymlosAbaloparatide | 12 | $31,077 |
| XareltoRivaroxaban | 33 | $24,795 |
| FarxigaDapagliflozin Propanediol | 26 | $24,123 |
| GemtesaVibegron | 15 | $19,291 |
| JardianceEmpagliflozin | 18 | $17,446 |
| MyrbetriqMirabegron | 16 | $16,874 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $15,905 |
| SynthroidLevothyroxine Sodium | 138 | $9,914 |
| Bupropion XlBupropion Hcl | 201 | $3,616 |
| Montelukast Sodium | 337 | $3,036 |
| Levothyroxine Sodium | 382 | $2,917 |
| PremproEstrogen,con/M-Progest Acet | 11 | $2,568 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $176 | $43,34747 claims |
| Novo NordiskOzempic | $53 | $41,23539 claims |
| PfizerEliquis, Prempro | $22 | $40,90343 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $53 | $19,29115 claims |
| Astellas Pharma US IncMyrbetriq | $335 | $16,87416 claims |
| GSKTrelegy Ellipta | $168 | $15,90526 claims |
| AbbVieSynthroid | $603 | $9,914138 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $2,917382 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Kerrville
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.